Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Accured Expenses (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Change in Accured Expenses for 12 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 436.73% year-over-year to $1.5 million, compared with a TTM value of $388000.0 through Sep 2025, down 72.36%, and an annual FY2024 reading of -$326000.0, down 156.6% over the prior year.
  • Change in Accured Expenses was $1.5 million for Q3 2025 at Fennec Pharmaceuticals, up from -$618000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.8 million in Q4 2023 and bottomed at -$1.3 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $86125.0, with a median of -$144000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 1666.67% in 2024, then skyrocketed 436.73% in 2025.
  • Year by year, Change in Accured Expenses stood at -$213000.0 in 2021, then surged by 956.81% to $1.8 million in 2022, then grew by 1.1% to $1.8 million in 2023, then tumbled by 93.77% to $115000.0 in 2024, then skyrocketed by 1183.48% to $1.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for FENC at $1.5 million in Q3 2025, -$618000.0 in Q2 2025, and -$585000.0 in Q1 2025.